

Parent/Carer Information Sheet

Project Title: Global Angelman Syndrome Registry

Principal Investigators:

A/Prof Honey Heussler	Lady Cilento Children's Hospital, Brisbane	h.heussler@health.qld.gov.au	Tel +61(7) 3163 1636
Prof Katrina Williams	Royal Children's Hospital, Melbourne	katrina.williams@mcri.edu.au	Tel +61(3) 9345 5898
Megan Tones (registry curator)	Mater Research, Brisbane	curator@angelmanregistry.info	TBC

You are being invited to take part in a global registry as the parent/ caregiver of an individual (either a child or an adult) who has a diagnosis of Angelman Syndrome (AS). Before you accept or decline the invitation, it is important for you to understand why this registry has been built and what it will involve. Please read this information sheet and discuss it with relatives, friends and clinicians caring for your child/ adult with AS, if you wish. If you have any further questions, please contact a member of the research team above.

Participation in the registry is voluntary. Please take the time to decide whether you would like to take part, or not.

Project Overview

The Global Angelman Syndrome Registry is being initiated by the Foundation for Angelman Syndrome Therapeutics (FAST) Australia with support from Mater Research in Brisbane and the Royal Children's Hospital in Melbourne. FAST Australia is an organisation of families and professionals dedicated to finding a cure for Angelman Syndrome and related disorders through funding research, education, and advocacy. The Foundation is committed to assisting individuals living with Angelman Syndrome to realise their full potential and quality of life. We are confident that our goals are now within reach and together, with your help, we will change lives. Established in 2010, FAST Australia is a Health Promotion Charity with DGR status that is registered with the Australian Charities and Not-for-Profits Commission (ACNC).

The registry is being coordinated in Queensland by Mater Research, and is being supported by the Royal Children's Hospital in Melbourne. The lead researcher in Queensland is Associate Professor Honey Heussler from the Lady Cilento Children's Hospital. Professor Katrina Williams heads the contribution of the Royal Children's Hospital in Melbourne. The Global Angelman Syndrome Registry was created using the Rare Disease Registry Framework (RDRF), which was developed by the Centre for Comparative Genomics at Murdoch University.

The aim of the registry is to establish an electronic repository containing information about your individual affected by Angelman Syndrome. Having an electronic record of individuals with AS means that we can identify groups of individuals with AS from all over the world, who might be able to participate in clinical trials and other research to help develop new therapies for AS. The registry will contain all the data that researchers will need, including each child/ adult's diagnosis, symptoms and other important aspects of their disorder.

Registry data collected over time will also be used to compile a natural history data set for individuals with Angelman Syndrome. Descriptive and statistical analysis techniques will be used to develop an understanding of the health and medical, behavioural and developmental outcomes of individuals with Angelman Syndrome according to phenotype, genotype or other characteristics of their diagnosis, as well as demographic factors. This may help to enhance understanding of the long term clinical outcomes and natural history of AS, which may help to shape future research in treating this disorder. Third party researchers not affiliated with this project may also apply to the Global Angelman Syndrome Registry governance committee to 1) access de-identified (anonymised) data for research purposes or 2) access identifiable data with the permission of participants.

De identified data from the Global Angelman Syndrome Registry will be accessible online via a translational research platform called TranSMART to inform research and educate parents/caregivers, researchers, clinicians, pharmaceutical and other interested parties . TranSMART is a cloud based data sharing platform that allows comprehensive informatics-based analysis for the purposes of clinical and translational research. Any data which may identify a registry participant such as date of birth or address, or may potentially identify an individual (such as rare genotype or remote location), is removed before the information is uploaded into the TranSMART platform.

Clarivate Analytics has been engaged under contract by FAST Australia to install and manage the TranSMART platform. Clarivate will at no stage be given access to data from the Global Angelman Syndrome Registry that identifies individuals. As contractors engaged to manage the anonymised data, Clarivate shall comply with all applicable laws and regulations relating to privacy, security, and data protection of such clinical data. If you do not wish for your child/ adult's data to be accessed through the TranSMART platform, you have the option of not consenting to your child/ adult's data being made available via the TranSMART online platform.

See the sections **“Will information about me and my child/ adult be kept confidential?”** and **“How will my child/ adult's data be used?”** for further information below.

The registry is patient driven, meaning that parents and caregivers take an active role in participating in the registry. Recruitment for the registry takes place online via participating global Angelman Syndrome organisations, which provide links to the online registry.

Before you consider registering your child/ adult's details, it is important that you understand what is involved and what will be done with the information you provide. This form contains answers to some of the questions you might have on the registry. At the end of the form, and after you have had some time to think about it, we shall ask if you wish to register.

If you do, we shall ask you to submit an online consent form saying that you agree to join to start entering data into the registry. If you have any questions, please contact us before consenting to join the registry.

How will I benefit from registering?

This registry aims to benefit individuals living with AS. You will be contacted as a parent/ caregiver of a child/ adult with AS when requests from doctors or researchers are received to help assess possible new treatments (clinical trials). Secure records of your child/ adult's clinical details will be used to determine whether or not such trials would be suitable for your child/ adult with AS. If you consent, you will be contacted using the details you provide to the registry to advise of upcoming trials or studies you may wish to take part in. Your name will not be given to researchers or external groups, rather you will be given information required should you wish to be involved. You will not receive any payment or any other financial benefit as a result of joining the registry. The results of research arising from the registry may have business potential (if for example utilised by a pharmaceutical company to develop a new drug) but you will not receive financial benefits from such development. Your data can become part of a larger dataset that does not contain any identifying information that can be accessed using the online platform TranSMART, allowing comprehensive informatics-

based analysis for clinical and translational research and helping to further research and understanding into Angelman Syndrome. Parents and caregivers will also be able to access the online data.

Other possible benefits to being involved in the registry are:

1. You will be informed as a parent/ caregiver about suitable clinical trials that your child/ adult with AS might be eligible to join.
2. The details collected will also provide information for doctors interested in the best standards of care for Angelman Syndrome.
3. Information collected in the registry may help to progress research into the study of Angelman Syndrome.
4. The information may help with service planning for people with Angelman Syndrome and their families in various locations.

What information will I be asked to provide about my child/ adult with Angelman Syndrome?

Once you have consented to participate in the registry you will be able to complete a series of modules that will take approximately 1.5 to 2 hours to complete. We suggest that you collect any information you have on your child/ adult's diagnosis, tests and development to make this process easier (however they can be added at a later date). Similarly if you find that you don't have enough time to complete all the information in one block you can login again and complete at a later date.

The current modules are:

- | | |
|-------------------------------------|---|
| 0. Demographics | 6. Epilepsy |
| 1. Newborn and infancy history | 7. Medications and interventions |
| 2. History of diagnosis and results | 8. Sleep |
| 3. Illnesses or medical problems | 9. Sleep Disturbance Scale for Children |
| 4. Medical history | 10. Pathology and Diagnostics |
| 5. Behaviour and Development | 11. Additional Information |

You will be asked each year to review the information that you have provided about the individual with AS and update any changes to their condition. Additional modules may also be added over time.

I want my child/ adult with AS to be involved in a clinical trial. If I register, is this guaranteed?

No. Although one of the main aims of this registry is to make it easier for individuals with AS to be recruited for clinical trials, there is no guarantee that providing your details will mean you will be automatically approached to take part in a clinical trial. For example, if the researchers are looking for individuals who have UPD only, we would let all of those who have UPD know that a trial is coming up.

Doctors or researchers coordinating a clinical trial may approach the registry governance committee to provide details about the clinical trial and eligibility requirements. If the clinical trial satisfies the requirements of the registry governance committee, the principal investigators and curator will review the details of suitable trial candidates and provide contact details for the doctor/ researchers conducting the trial.

Please note that the doctors/ researchers conducting the trial may need to assess the child/ adult with AS in greater detail, during which it may be clear that other developments in their health or details not recorded on the registry mean that the trial is not suitable for them.

Will information about me and my child/ adult be kept confidential?

All information received will be treated confidentially. Every effort will be made to ensure your data is kept safe but we remind you to be vigilant when entering information online. Details of your child/ adult's specific diagnosis as well as personal information about you and your child/ adult (name, age, address, gender) will be stored on the database. This information is all required to enable us to match you with criteria for prospective clinical trials and better understand Angelman Syndrome. Only doctors and scientists involved in this project who are given specific permission will be allowed to look at this information. The information you provide can be made available to your treating doctor if you consent to this. If any research or other documents based on information from the registry is published, they will not identify you by name.

The Foundation for Angelman Syndrome Therapeutics Australia, and participating global partners in this project, along with associated researchers do not have access to any personal details or identifying information. If the Foundation for Angelman Syndrome Therapeutics Australia or any participating global partners request identifying information they will be subject to the same requirements as any other application for data and you will be contacted by the data curator prior to such information being provided(see below **How will my child/ adult's data be used?**).

Please note that non identifiable data must be stored for a minimum of 15 years as required by Australian government regulations (National Health & Medical Research Council Guidelines). In the case of children, data must be stored up until they reach the age of 18 years, and 15 years thereafter. The research team will take all reasonable steps to protect participants' personal information and data against breaches of security or loss in accordance with the Federal Privacy Act.

Do I have to enrol my child/ adult with AS in the registry and can I withdraw if I change my mind?

Enrolling your child/ adult with AS in the registry is voluntary. Should you wish to withdraw your child/ adult's information from the registry you will be free to do so at any time without having to provide any explanation. If you wish to withdraw your child/ adult with AS from the registry, you should get in touch with the registry curator. Contact details are provided above. Joining or leaving the registry will in no way affect the care your child/ adult receives for his/ her condition.

How will my child/ adult's data be used?

One of the main aims for participation in the registry is to help recruitment into clinical trials. However the data may also be used to learn more about people with Angelman Syndrome. The information you provide may be used to help researchers design future investigations. Any data released for research will not identify you or your child/ adult by name.

Your child/ adult's de-identified (anonymous) data may be accessed as part of the full Angelman Syndrome registry data set by external researchers not involved with the registry wishing to conduct their own research into Angelman Syndrome. All external researchers must do the following to access the de-identified data:

1. Submit a research proposal to the Global Angelman Syndrome Registry governance committee (the governance committee), who will decide whether the external research meets the standards and aims of the registry; and
2. Show evidence of ethical clearance to conduct their research from an independent ethical review board.

The governance committee will make every endeavour to ensure external researchers understand their obligations regarding protecting your privacy. However, please note that data protection laws may differ from the Federal Privacy Act outside of Australia. For clinical trials and other research where identifiable information is necessary, we will contact you directly about the study if you provide consent for us to do so. You will then be able to make a decision about whether you wish to participate in the trial. As per the Federal Privacy Act, your personal information will never be provided to external party researchers. However, please note that if your child/ adult with AS has a rare mutation or other distinct feature your information may be identifiable by those who are aware of your child/ adult's condition.

How will our details be updated?

You will be able to update any registry details via the web page including parent/ caregiver contact details or any changes to your child/ adult with Angelman Syndrome's condition. You will be sent a yearly reminder to update information about your child/ adult with Angelman Syndrome's condition. However, you may also need to update information about your child/ adult's condition at other times, such as following clinic visits. You may also contact us at any time if you need to amend your details. Each year you will be contacted to see if you are still happy to have your details included on the registry. You are free to have your child/ adult's information withdrawn from the registry at any time. If you have provided consent for us to do so, we will also contact the clinician in charge of your child/ adult's medical care so we verify your child/ adult's Angelman Syndrome Diagnosis.

Who is funding the research?

This study has been funded by the Foundation for Angelman Syndrome Therapeutics (FAST) Australia and there is no conflict of interest on the part of any of the researchers.

Who has reviewed this project?

This study has been reviewed and approved by the Mater Misericordiae Ltd Human Research Ethics Committee (EC00332). Should you wish to discuss the study in relation to your rights as a participant, or should you wish to make an independent complaint, you may contact the Coordinator or Chairperson, Human Research Ethics Committee, Mater Misericordiae Ltd, Level 2 Aubigny Place, Raymond Terrace South Brisbane 4101 or telephone (07) 3163 1585, email: research.ethics@mmri.mater.org.au.

What if I have any concerns?

If you have any concerns or other questions about this study or the way it has been carried out, you should contact the data curator, Dr Megan Tones at curator@angelmanregistry.info.

Alternatively, you may contact one of the other investigators on the telephone numbers or email addresses provided on page 1 of this document.

Should you wish to discuss the study in relation to your rights as a participant, or should you wish to make an independent complaint, you may contact the Coordinator or Chairperson, Human Research Ethics Committee, Mater Research Level 2 Aubigny Place, Raymond Terrace South Brisbane 4101 or telephone +617 3163 1585, email: research.ethics@mmri.mater.org.au.

In addition, if you have any complaints or concerns specific to data security, you may wish to contact the Australian Federal Privacy Commissioner: telephone: 1300 363 992; email: enquiries@oaic.gov.au.

Thank you for taking the time to read this information sheet

CONSENT FORM FOR PARENTS/ CARERS

Global Angelman Syndrome Registry

Name of Researcher:

A/Prof Honey Heussler Mater Research, Brisbane

Please provide your informed consent by checking the boxes below. Consent questions 1 – 8 are required for inclusion in the registry, while consent questions 9 - 12 are optional.

A copy of the Parent/ Carer Information presented here is available by clicking on the "Information Sheet - Please Read!" link at the top of this page. There is no need to sign or upload this form unless you are giving consent for the research team to contact your clinician on your behalf (see item 9 below).

1. I confirm that I have read and understand the information sheet (V9) dated 8 November 2017, for the above study. I have had the opportunity to consider the information, ask questions and have had these answered satisfactorily.	Mandatory
2. I understand that my participation is voluntary and that I am free to withdraw at any time, without giving any reason, without my medical care or legal rights being affected.	Mandatory
3. By entering data into the registry, I understand that I give consent for the storage of data on my child/ adult with Angelman Syndrome in the Global Angelman Syndrome Registry.	Mandatory
4. I understand that the storing of data will allow contact to be made with me if a suitable clinical trial/ research study becomes available for my child/ adult with Angelman Syndrome.	Mandatory
5. However, I accept that allowing my data to be stored on this database does not mean my child/ adult with Angelman Syndrome will automatically be entered into future clinical trials/ research studies.	Mandatory
6. I understand that the data I provide may be used to inform and plan future research.	Mandatory
7. I understand that the results from future research may not have any direct implications for me or my family.	Mandatory
8. I am happy to consent for my child/ adult with AS to be included in this registry.	Mandatory
9. I confirm I am happy for the specialist in charge of my medical care to be contacted to verify diagnostic information.	Not mandatory
10. I confirm that I am happy for my de-identified data to be made available for analysis through the third party platform TranSMART	Not mandatory
11. I consent to being contacted to complete additional modules/ for longitudinal follow up.	Not mandatory
12. I consent to being contacted about clinical trials and research studies that my child/ adult with Angelman Syndrome may be eligible to participate in.	Not mandatory

Please sign here (parent/ caregiver): _____

Name of Patient: _____

Date Signature: _____